Company: MDCXW
Filing Date: 2025-08-04
Form Type: 8-K
Source: 0001062993-25-013468
Chunk: 0

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-04
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On August 4, 2025, Medicus Pharma Ltd. (the "Company") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vaccines and therapies to augment the immune system's power to fight disease, announced that they have entered into a non-binding memorandum of understanding (the "MoU") in respect of their shared mutual interest in the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus' proprietary MNA delivery platform. Subject to the certain conditions noted in the MoU, Medicus and HelixNano are currently engaged in good faith negotiations with the aim of forming a joint venture (the "Joint Venture") for the co-development and commercialization of thermostable mRNA-based vaccines utilizing their respective proprietary technologies. In parallel with such ongoing negotiations, Medicus and HelixNano have formalized their mutual intent to collaborate on the research, development and production of a batch of clinical-grade mRNA vaccine-loaded MNAs (the "Project"), which are intended for use in a Phase 1 clinical bridging study to compare the safety and preliminary efficacy of intramuscular injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001, through the proposed Joint Venture.

The purpose of the MoU is to memorialize the mutual intention of the parties to proceed with preliminary collaborative efforts towards the Project while the terms of the contemplated Joint Venture are being finalized. Except as expressly provided in certain sections, the MoU is non-binding and shall not be construed to obligate either party to proceed with the Joint Venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

A copy of the press release announcing the MOU, issued by the Company on August 4, 2025, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit      Description                                                            
      No.                                                                             
     99.1      Press Release, dated August 4, 2025.                                   
 ──────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (formatted as Inline XBRL document).  

Forward Looking Statements

Certain information in this Current Report on Form 8-K constitutes "forward-looking statements" under applicable securities laws. "